SCHEMBL1877259

SCHEMBL1877259

COc1ccc(CCN)cc1N

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.72
ATM Q13315 1/20 0.72
GAA P10253 1/20 0.69
TSHR P16473 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP1A2 P05177 1/20 0.66
NFKB1 P19838 1/20 0.66
LMNA P02545 2/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
APEX1 P27695 1/20 0.64
TAAR1 Q96RJ0 5/20 0.62
MAPK1 P28482 1/20 0.62
GLA P06280 1/20 0.61
CYP19A1 P11511 1/20 0.58
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
HTR2B P41595 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090146 0.90 GAA (0.77) KDM4EATMGAATSHRCYP3A4
SCHEMBL13181092 0.85 GAA (0.69) KDM4EATMGAATSHRCYP3A4
SCHEMBL2019108 0.85 KDM4E (0.72) KDM4EATMTSHRCYP3A4CYP1A2
SCHEMBL29351641 0.84 ATM (1.00) KDM4EATMTSHRCYP3A4CYP1A2
SCHEMBL1725006 0.84 GAA (0.74) KDM4EATMGAATSHRCYP3A4
SCHEMBL210639 0.84 ATM (1.00) KDM4EATMTSHRCYP3A4CYP1A2
SCHEMBL687841 0.83 GAA (0.67) KDM4EATMGAATSHRCYP3A4
SCHEMBL8867396 0.83 GAA (0.67) KDM4EATMGAATSHRCYP3A4
SCHEMBL30135970 0.83 GAA (0.67) KDM4EATMGAATSHRCYP3A4
SCHEMBL28186288 0.83 GAA (0.67) KDM4EATMGAATSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180111905-A1 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-26 US disclosed
US-20180111905-A1 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-26 US disclosed
WO-2016167511-A2 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT 한국화학연구원 2016-10-20 WO disclosed
US-20110207860-A1 Inkjet Ink Compositions Comprising Polymeric Dispersants Having Attached Chromophore Groups CABOT CORPORATION (US) 2011-08-25 US disclosed
US-20110207860-A1 Inkjet Ink Compositions Comprising Polymeric Dispersants Having Attached Chromophore Groups CABOT CORPORATION (US) 2011-08-25 US disclosed
US-7947761-B2 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION (US) 2011-05-24 US disclosed
US-7947761-B2 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION (US) 2011-05-24 US disclosed
US-7947761-B2 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION (US) 2011-05-24 US disclosed
EP-1981943-A1 INKJET INK COMPOSITIONS COMPRISING POLYMERIC DISPERSANTS HAVING ATTACHED CHROMOPHORE GROUPS Cabot Corporation (US) 2008-10-22 EP disclosed
WO-2007089859-A1 INKJET INK COMPOSITIONS COMPRISING POLYMERIC DISPERSANTS HAVING ATTACHED CHROMOPHORE GROUPS CABOT CORPORATION (US) 2007-08-09 WO disclosed
US-20070179214-A1 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION 2007-08-02 US disclosed
US-20070179215-A1 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION 2007-08-02 US disclosed
US-20070179215-A1 Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups CABOT CORPORATION 2007-08-02 US disclosed
CN-1075808-C Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-12-05 CN disclosed
CN-1310169-A Anils with nitric oxide synzyme inhibiting function SHUGAI SEIYAKU K K (JP) 2001-08-29 CN disclosed
CN-1172473-A Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-02-04 CN disclosed
EP-0175525-B1 7-[2-(Dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones SMITHKLINE BEECHAM CORPORATION (US) 1990-05-23 EP disclosed
US-4593106-A 4-[2-(dialkylamino)ethyl]-7-hydroxyisatins SMITHKLINE BECKMAN CORPORATION (US) 1986-06-03 US disclosed
EP-0175525-A1 7-[2-(Dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones SMITHKLINE BEECHAM CORPORATION (US) 1986-03-26 EP disclosed
US-4554287-A Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones SMITHKLINE BECKMAN CORPORATION (US) 1985-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111905-A1 N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT ALK, NPM1, EML4 KDM4E 756/4885ATM 1285/4885GAA 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.